Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17312333 | 1.00 | GAA (0.47) | GAATDP1TSHRALDH1A1NFKB1 | |
| SCHEMBL9521629 | 0.89 | ALDH1A1 (0.47) | GAATDP1TSHRALDH1A1NFKB1 | |
| SCHEMBL6162414 | 0.87 | CYP4F2 (0.41) | ALDH1A1CYP1A2CFDCYP4F2CYP4A11 | |
| SCHEMBL5673785 | 0.85 | ALDH1A1 (0.60) | GAATDP1TSHRALDH1A1NFKB1 | |
| SCHEMBL2593397 | 0.85 | ALDH1A1 (0.60) | GAATDP1TSHRALDH1A1NFKB1 | |
| SCHEMBL5690941 | 0.84 | MTNR1A (0.43) | ALDH1A1CYP1A2CFDCYP4F2CYP4A11 | |
| SCHEMBL11166903 | 0.82 | MEN1 (0.41) | GAATDP1TSHRALDH1A1NFKB1 | |
| SCHEMBL6221035 | 0.80 | GAA (0.56) | GAATDP1TSHRALDH1A1NFKB1 | |
| SCHEMBL9360555 | 0.80 | GAA (0.56) | GAATDP1TSHRALDH1A1NFKB1 | |
| Methane SCHEMBL10372267 | 0.79 | GAA (0.54) | GAATDP1TSHRALDH1A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| EP-1177181-B1 | SUBSTITUTED BICYCLIC COMPOUNDS | AVENTIS PHARMA LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| EP-1183254-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS | AVENTIS PHARMA LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-6706738-B2 | ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMA LIMITED (GB) | 2004-03-16 | — | — | US | disclosed |
| US-6562851-B2 | Antiinflammatory and antiasthmatic agents; inhibitors of alpha4 beta1 mediated cell adhesion | AVENTIS PHARMA LIMITED (GB) | 2003-05-13 | — | — | US | disclosed |
| US-20020173506-A1 | Substituted bicyclic heteroaryl compounds and their use as integrin antagonists | AVENTIS PHARMA LIMITED (GB) | 2002-11-21 | — | — | US | disclosed |
| US-20020156111-A1 | Substituted bicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2002-10-24 | — | — | US | disclosed |
| EP-1183254-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS | Aventis Pharma Limited (GB) | 2002-03-06 | — | — | EP | disclosed |
| EP-1177181-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | Aventis Pharma Limited (GB) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000068213-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | AVENTIS PHARMA LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000061580-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS | AVENTIS PHARMA LIMITED (GB) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173506-A1 | Substituted bicyclic heteroaryl compounds and their use as integrin antagonists | VCAM1, ITGA4, ITGA1 | GAA 4378/4885TDP1 4572/4885TSHR 1096/4885 |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | GAA 1058/4885TDP1 4089/4885TSHR 3054/4885 |
| US-20020156111-A1 | Substituted bicyclic compounds | VCAM1, ITGA1, ITGA5 | GAA 4161/4885TDP1 4419/4885TSHR 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.